Stock RVTY REVVITY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Revvity, Inc.

Equities

RVTY

US7140461093

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX
Other stock markets
 16:44:01 30/04/2024 BST 		5-day change 1st Jan Change
103.8 USD -1.20% Intraday chart for Revvity, Inc. +0.28% -5.05%
03:22pm TD Cowen Adjusts Price Target on Revvity to $130 From $123 MT
01:32pm JPMorgan Adjusts Price Target on Revvity to $105 From $100, Neutral Rating Maintained MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,788 16,068 25,374 17,712 13,490 12,973 - -
Enterprise Value (EV) 1 12,670 17,657 29,739 21,652 16,476 15,356 14,986 15,191
P/E ratio 47.6 x 22.1 x 25.2 x 30.6 x 19.7 x 48.4 x 37 x 31.7 x
Yield 0.29% 0.2% 0.14% - 0.26% 0.26% 0.26% 0.26%
Capitalization / Revenue 3.74 x 4.25 x 5 x 3.84 x 4.9 x 4.64 x 4.32 x 4.02 x
EV / Revenue 4.39 x 4.67 x 5.87 x 4.7 x 5.99 x 5.49 x 5 x 4.71 x
EV / EBITDA 19.6 x 14 x 16.2 x 15.2 x 19.7 x 17.9 x 15.9 x 14.7 x
EV / FCF 44.1 x 21.7 x 22.7 x 36.4 x 1,664 x 29.4 x 22.8 x 21.2 x
FCF Yield 2.27% 4.61% 4.41% 2.74% 0.06% 3.4% 4.38% 4.72%
Price to Book 3.85 x 4.31 x 3.55 x - 1.73 x 1.63 x 1.55 x 1.49 x
Nbr of stocks (in thousands) 111,101 111,974 126,200 126,316 123,407 123,525 - -
Reference price 2 97.10 143.5 201.1 140.2 109.3 105.0 105.0 105.0
Announcement Date 27/01/20 02/02/21 01/02/22 14/02/23 01/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,884 3,784 5,070 4,611 2,751 2,795 3,000 3,225
EBITDA 1 645.7 1,257 1,838 1,421 836.5 857.2 940.5 1,031
EBIT 1 596 1,203 1,771 1,381 769.9 782.3 864.3 952.3
Operating Margin 20.66% 31.8% 34.93% 29.95% 27.98% 27.99% 28.81% 29.53%
Earnings before Tax (EBT) 1 237.1 906.4 1,280 - 183 315.3 409.4 476.7
Net income 1 227.6 727.9 932.2 579.2 693.1 271.4 351.5 400.2
Net margin 7.89% 19.24% 18.39% 12.56% 25.19% 9.71% 11.72% 12.41%
EPS 2 2.040 6.490 7.990 4.580 5.550 2.170 2.840 3.313
Free Cash Flow 1 287.1 814.7 1,311 594.2 9.904 521.7 656.2 717.6
FCF margin 9.95% 21.53% 25.86% 12.89% 0.36% 18.66% 21.88% 22.25%
FCF Conversion (EBITDA) 44.47% 64.8% 71.3% 41.83% 1.18% 60.86% 69.78% 69.57%
FCF Conversion (Net income) 126.18% 111.92% 140.63% 102.59% 1.43% 192.23% 186.71% 179.31%
Dividend per Share 2 0.2800 0.2800 0.2800 - 0.2800 0.2762 0.2750 0.2733
Announcement Date 27/01/20 02/02/21 01/02/22 14/02/23 01/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1,167 1,365 1,260 1,230 1,033 1,089 675.1 709.3 670.9 696.1 650.1 692.1 698.4 752.8 701.7
EBITDA 1 375 478.2 427.2 420.4 282.6 311.9 206.4 220.5 202 207.7 182.4 210 215.1 247.9 216.4
EBIT 1 358.9 458.7 409.8 401.9 271.7 297.8 189.2 204.3 184.6 191.8 165.8 190.8 195.6 230.4 188.4
Operating Margin 30.75% 33.62% 32.53% 32.68% 26.31% 27.35% 28.03% 28.8% 27.51% 27.55% 25.5% 27.57% 28.01% 30.6% 26.85%
Earnings before Tax (EBT) 1 - - - - - - 29.44 71.55 50.6 31.38 34.55 85.25 80.39 120.4 81.57
Net income 1 127.7 179.2 177 179.2 85.35 137.7 569.5 35.56 9.497 78.56 26.01 67.63 67.88 107.1 61.4
Net margin 10.95% 13.13% 14.05% 14.57% 8.27% 12.64% 84.36% 5.01% 1.42% 11.29% 4% 9.77% 9.72% 14.23% 8.75%
EPS 2 1.110 1.410 1.400 1.420 0.6700 1.090 4.500 0.2800 0.0800 0.6400 0.2100 0.5467 0.5400 0.8467 0.5200
Dividend per Share 2 0.0700 0.0700 0.0700 0.0700 0.0700 - 0.0700 0.0700 - 0.0700 0.0700 0.0700 0.0700 0.0700 0.0700
Announcement Date 02/11/21 01/02/22 03/05/22 01/08/22 08/11/22 14/02/23 11/05/23 01/08/23 30/10/23 01/02/24 29/04/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,882 1,589 4,366 3,940 2,986 2,384 2,013 2,219
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.915 x 1.264 x 2.375 x 2.773 x 3.57 x 2.781 x 2.141 x 2.151 x
Free Cash Flow 1 287 815 1,311 594 9.9 522 656 718
ROE (net income / shareholders' equity) 16.9% 22.2% 17.2% 13.8% 5.57% 7.42% 7.93% 8.59%
ROA (Net income/ Total Assets) 7.31% 10% 8.11% 6.9% 3.07% 4.28% 4.99% 5.93%
Assets 1 3,115 7,274 11,488 8,392 22,588 6,337 7,047 6,745
Book Value Per Share 2 25.20 33.30 56.60 - 63.10 64.30 67.70 70.60
Cash Flow per Share 2 3.260 7.960 12.10 5.380 0.7300 6.220 5.970 6.930
Capex 1 76.3 77.5 99.9 85.6 81.4 79.4 81.8 87.3
Capex / Sales 2.65% 2.05% 1.97% 1.86% 2.96% 2.84% 2.73% 2.71%
Announcement Date 27/01/20 02/02/21 01/02/22 14/02/23 01/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Revvity, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
105 USD
Average target price
123.7 USD
Spread / Average Target
+17.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
REVVITY, INC. Stock Revvity, Inc.
-5.05% 12.97B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.97% 220B
DANAHER CORPORATION Stock Danaher Corporation
+6.33% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+9.84% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+24.27% 107B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-0.87% 63.05B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+11.83% 51.74B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.81% 50.47B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.12% 40.91B
RESMED, INC. Stock ResMed, Inc.
+23.68% 31.91B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. RVTY Stock
  4. Financials Revvity, Inc.